Novo Nordisk A/S (NYSE:NVO) Shares Bought by Princeton Global Asset Management LLC

Princeton Global Asset Management LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 56.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,781 shares of the company’s stock after purchasing an additional 1,000 shares during the period. Princeton Global Asset Management LLC’s holdings in Novo Nordisk A/S were worth $239,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Raymond James & Associates boosted its position in shares of Novo Nordisk A/S by 1.0% in the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after purchasing an additional 36,223 shares during the period. Natixis Advisors LLC boosted its position in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the period. International Assets Investment Management LLC boosted its position in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares during the period. LPL Financial LLC boosted its position in Novo Nordisk A/S by 3.6% during the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock worth $162,266,000 after acquiring an additional 47,496 shares during the period. Finally, DAVENPORT & Co LLC boosted its position in Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after acquiring an additional 451,641 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on NVO shares. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $82.64 on Tuesday. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The firm has a market capitalization of $370.85 billion, a PE ratio of 26.74, a PEG ratio of 0.93 and a beta of 0.45. The business’s 50 day moving average is $93.56 and its 200-day moving average is $112.87. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.